Clinical relevance of gene mutations in acute myeloid leukemia with normal karyotype

Česká verzia

Authors: B. Katrincsáková; T. Szotkowski; M. Divoká; K. Indrák; M. Jarošová
Authors place of work: Hemato-onkologická klinika Fakultní nemocnice Olomouc
Published in the journal: Transfuze Hematol. dnes,17, 2011, No. 2, p. 72-80.
Category: Souhrnné práce, původní práce, kazuistiky

Summary

Acute myeloid leukemia (AML) is characterized by distinct clinical and genetic heterogeneity. Chromosomal aberrations are present in about 55% of patients at the time of diagnosis however a large group of AML (about 45%) comprise patients with normal karyotype (NK-AML). In the latter group, gene mutations and changes in expression profiles enable us to allocate subsets with different prognosis. In NK-AML specific mutation profiles are associated with worse prognosis (FLT3-ITD, MLL-PTD mutations) or mark for better prognosis (isolated NPM1 and CEBPA mutations, NPM1mutated AML without FLT3-ITD). Treatment decisions based on molecular stratification however, remain controversial. This review assesses the current insight on the prognostic and therapeutic significance of gene mutations in NK-AML.

Key words:
AML, normal karyotype, mutation, molecular markers, FLT3, NPM1, CEBPA, WT1, IDH1/2

Zdroje

1. Estey E, Döhner H. Acute myeloid leukaemia. Lancet 2006 Nov 25; 368 (9550): 1894-907.

2. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 2010 Jan 21; 115(3): 453-74.

3. Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007 Jan 15; 109(2): 431-48.

4. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.

5. Döhner K, Döhner H. Molecular characterization of acute myeloid leukemia. Haematologica 2008 Jul; 93(7): 976-82.

6. Gazdová J, Dvořáková D, Ježíšková I, Rázga F, Jurček T, Mayer J. Úloha FLT3 mutací v patogenezi akutní myeloidní leukemie. Transfuze Hematol dnes 2009 Prosinec; 15: 229-236.

7. Thiede C, Steudel C, Mohr B, et al Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002 Jun 15; 99(12): 4326-35.

8. Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 2005 Aug; 19(8): 1345-9.

9. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111(5): 2776–84.

10. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res 2001; 61(19): 7233–9.

11. Kottaridis PD, Gale RE, Langabeer SE , et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002 Oct 1; 100(7): 2393-8.

12. Schnittger S, Schoch C, Kern W, et al. FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia. Acta Haematol 2004; 112(1-2): 68-78.

13. Beretta C, Gaipa G, Rossi V, et al. Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia. Leukemia 2004 Aug; 18(8): 1441-4.

14. Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008 Feb 1; 111(3): 1552-9.

15. Bacher U, Haferlach C, Kern W, et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients. Blood 2008 Mar 1; 111(5): 2527-37.

16. Schlenk RF, Döhner K, Krauter J, et al Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008 May 1; 358(18): 1909-18.

17. Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 2005 Nov 15; 106(10): 3658-65.

18. Doubek M, Muzík J, Szotkowski T, et al. Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT). Neoplasma 2007; 54(1): 89-94.

19. Wagner K, Damm F, Thol F, et al. FLT3-internal tandem duplication and age are the major prognostic factors in relapsed acute myeloid leukemia with normal karyotype. Haematologica 2011 Jan 17 (Epub ahead of print).

20. Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 2009 Jun; 12(3): 81-9.

21. Falini B, Sportoletti P, Martelli MP. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol 2009; 21: 573–581.

22. Rau R, Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol 2009 Dec; 27(4): 171-81.

23. Schnittger S, Schoch C, Kern W, et al Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005 Dec 1; 106(12): 3733-9.

24. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010 Feb 1; 28(4): 596-604.

25. Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics:interaction with other gene mutations. Blood 2005 Dec 1; 106(12): 3740-6.

26. Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009 Sep 10; 114(11): 2220-31.

27. Schlenk RF, Döhner K, Kneba M, et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia: results from the AMLSG Trial AML HD98B. Haematologica 2009; 94: 54-60.

28. Burnett AK, Hills RK, Green C, et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 2010 Feb 4; 115(5): 948-56.

29. Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001; 27: 263–270.

30. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA 1997; 94(2): 569-574.

31. Rosenbauer F, Tenen DG. Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol 2007; 7(2): 105-117.

32. Reckzeh K, Cammenga J. Molecular mechanisms underlying deregulation of C/EBPalpha in acute myeloid leukemia. Int J Hematol 2010 May; 91(4): 557-68.

33. Fröhling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004 Feb 15; 22(4): 624-33.

34. Taskesen E, Bullinger L, Corbacioglu A. et al Prognostic impact, concurrent genetic mutations and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2010 Dec 21 (Epub ahead of print).

35. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010 Jun 1; 28(16): 2739-47.

36. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009; 113(13): 3088-3091.

37. Renneville A, Boissel N, Gachard N, et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood 2009 May 21; 113(21): 5090-3.

38. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica 2009 Jul; 94(7): 984-93.

39. Basecke J, Whelan JT, Griesinger F, Bertrand FE. The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol 2006 Nov; 135(4): 438-49.

40. Whitman SP, Ruppert AS, Marcucci G, et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood 2007 Jun 15; 109(12): 5164-7.

41. Olesen LH, Nyvold CG, Aggerholm A, NŅrgaard JM, Guldberg P, Hokland P. Delineation and molecular characterization of acute myeloid leukemia patients with coduplication of FLT3 and MLL. Eur J Haematol 2005 Sep; 75(3): 185-92.

42. Whitman SP, Liu S, Vukosavljevic T, et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood 2005 Jul 1; 106(1): 345-52.

43. Polák J, Marková J, Schwarz J, et al. The use of quantitative assessment of Wilms tumour gene 1 for monitoring of residual disease in acute myeloid leukemia patients. Cas Lek Cesk 2006; 145(1): 36-42.

44. Owen C, Fitzgibbon J, Paschka P. The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia. Hematol Oncol 2010 Mar; 28(1): 13-9.

45. Gaidzik VI, Schlenk RF, Moschny S, et al. German-Austrian AML Study Group. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009 May 7; 113(19): 4505-11.

46. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009 Sep 10; 361(11): 1058-66.

47. Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 2010 Sep; 16(9): 387-97.

48. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010 Feb 15; 207(2): 339-44.

49. Marcucci G, Maharry K,Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2010; 28(14): 2348–55.

50. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010 Dec 14; 18(6): 553-67.

51. Boissel N, Nibourel O, Renneville A, et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 2010 Aug 10; 28(23): 3717-23.

52. Green CL, Evans CM, Hills RK, Burnett AK, Linch DC, Gale RE. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 2010 Oct 14; 116(15): 2779-82.

53. Chou WC, Hou HA, Chen CY, et al. Distinct clinical and biological characteristics in adult acute myeloid leukemia bearing isocitrate dehydrogenase 1 (IDH1) mutation. Blood 2010; 115: 2749–2754.